Court rules in favor of the New York Times over texts between an EU chief and a pharma boss

Article content

BRUSSELS (AP) — A top European court ruled on Wednesday that the European Commission was wrong to refuse the New York Times access to text messages sent between President Ursula von der Leyen and a pharmaceutical boss during the COVID-19 pandemic.

Article content

Article content

The U.S. newspaper’s lawyers “succeeded in rebutting the presumption of non-existence and of non-possession of the requested documents,” according to a statement from the European Union’s General Court in Luxembourg.

Article content

The case highlights ongoing questions about oversight of the commission, which insists that text messages and other “ephemeral” electronic communications do not necessarily constitute documents of interest that should be saved or made public.

Article content

Article content

A statement from the court said that “the commission cannot merely state that it does not hold the requested documents but must provide credible explanations enabling the public and the court to understand why those documents cannot be found.”

Article content

Article content

It said that the commission had failed to explain “in a plausible manner” why the messages did not contain important information.

Article content

It also said that the commission “has not sufficiently clarified whether the requested text messages were deleted and, if so, whether the deletion was done deliberately or automatically or whether the President’s mobile phone had been replaced in the meantime.”

Article content

Transparency advocates argue that the EU’s increasingly powerful executive branch should build a paper trail of all its dealings and release documents when asked.

Article content

The New York Times said texts were exchanged between Von der Leyen and Pfizer CEO Albert Bourla as COVID-19 ravaged communities from Portugal to Finland and the EU scrambled to buy billions of vaccines.

Article content

Von der Leyen was under intense scrutiny, especially after AstraZeneca stumbled to deliver vaccine doses to the 27-nation bloc.

Article content

Article content

Amid fierce international competition for the access to vaccines, von der Leyen was praised for her leading role during the pandemic, but she also found herself receiving sharp criticism for the opacity of the negotiations to quickly gather 2.7 billion euros ($2.95 billion) to place an order for more than a billion doses of vaccines.

Article content

At the same time as she was reported to be exchanging messages directly with the Pfizer boss, von der Leyen was publicly praising the company as ” a reliable partner.”

Article content

The commission has just over two months to launch an appeal to the European Court of Justice should it decide to contest Wednesday’s ruling.

Article content

_-

Article content

Lorne Cook in Brussels contributed to this report.

Article content